User talk:EGagnon7224/Sandbox
Notability:
(1) Onyx is a publicly traded biopharmaceutical company on NASDAQ under ONXX--http://finance.yahoo.com/q?s=ONXX.
(2) Onyx's profile on Hoover's: http://www.hoovers.com/onyx-pharmaceuticals/--ID__51415--/free-co-factsheet.xhtml.
(4) Recent analyst coverage of Onyx can be found here: http://finance.yahoo.com/q/ao?s=ONXX
(5) Onyx has receives regular media coverage from wires and top business outlets, some recent examples follow
- Gryta, Thomas. "Onyx Pharma Building Product Pipeline In Opportune Environment." Dow Jones. 26 March 2009.
- Chase, Marilyn and Dooren, Jennifer Corbett. "New Drugs Show Promise for Liver Cancer." The Wall Street Journal. 5 June 2007.
- http://www.bizjournals.com/sanfrancisco/stories/2008/07/21/story1.html
- http://finance.yahoo.com/news/Onyx-shares-rise-on-4Q-apf-14459115.html?.v=2
- http://www.fool.com/investing/high-growth/2009/02/24/5-stocks-approaching-greatness.aspx
(6) To view Onyx's 2008 annual report: http://www.onyx-pharm.com/pdf/Onyx_AR08.pdf
# # #
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), headquartered in Emeryville, California, is a biopharmaceutical company developing therapeutic drugs for cancer. It was established in The President and CEO is N. Anthony (Tony) Coles, M.D.; Paul Goddard, Ph.D. is chairman of the Board of Directors.
Products[edit]
Onyx’s lead product is Nexavar (sorafenib). [1] an oral multiple kinase inhibitor that targets proteins involved in tumor cell proliferation and angiogenesis. [2] [3][4][5] The product is being developed and marketed in collaboration with Bayer HealthCare Pharmaceuticals.[6][7]
Nexavar is approved in more than 70 countries for treatment of advanced renal cell carcinoma, and in more than 60 countries for treatment of hepatocellular carcinoma. [8] It is being evaluated in Phase 3 and Phase 2 trials for other cancers, alone or as part of combination therapy with other agents. [9][10]
There are several other products in development. In November 2008, Onyx in-licensed a targeted anticancer agent called ONX 0801 (formerly BCG 945) from BTG International Ltd.[11][12] This compound targets malignant cells that over-express the surface alpha-folate receptor. Once ONX 0801 enters the cell via this receptor, it inhibits thymidylate synthase (TS), a key enzyme in cell growth and division. This is distinct from currently marketed TS inhibitors for its selective tumor cell-specific uptake by the alpha-folate receptor. [13]
In December 2008, Onyx acquired license options to two inhibitors of Janus Kinase 2 (JAK2) from S*BIO Pte. Ltd.[14][15] The first, ONX 0803 (formerly SB1518), suppress overactivity of mutant JAK2 and is currently in Phase 1 studies for primary myelofibrosis.[16] ONX 0805 (formerly SB1578), the second compound, is still in preclinical development.
In addition, PD 332991, an small molecule CDK4 inhibitor, entered clinical testing in 2004 as a result of a collaboration with Warner-Lambert Company, now Pfizer. This compound intervenes in the misregulated cell cycle of tumor cells by inhibiting a key enzyme, cyclin-dependent kinase 4 (cdk4). [17]
References[edit]
- ^ Nexavar® tablets is a trademark of Bayer Healthcare Pharmaceuticals.
- ^ Llovet et al. (2008) “Sorafenib in advanced Hepatocellular Carcinoma.” New England Journal of Medicine, 359:378-90
- ^ Cheng et al. (2009) “Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.” The Lancet Oncology, 10: 25-34
- ^ Nexavar's label: http://www.fda.gov/cder/foi/label/2007/021923s004s005s006s007lbl.pdf
- ^ www.Nexavar.com
- ^ Nexavar. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails
- ^ Nexavar's label: http://www.fda.gov/cder/foi/label/2007/021923s004s005s006s007lbl.pdf
- ^ http://www.onyx-pharm.com/wt/page/marketed_products.
- ^ http://www.clinicaltrials.gov/ct2/results?term=sorafenib
- ^ http://www.onyx-pharm.com/wt/page/index
- ^ Douglas, Jason. Dow Jones International News. "BTG, Onyx Pharm Ink Potential $320M Cancer Drug Deal." 7 November 2008.
- ^ http://www.onyx-pharm.com/wt/page/pr_1225998531
- ^ http://cancerres.aacrjournals.org/cgi/content/abstract/65/24/11721?ck=nck “BGC 945, a Novel Tumor-Selective Thymidylate Synthase Inhibitor Targeted to A-Folate Receptor–Overexpressing Tumors,” Jackman et al. Cancer Research 2005.
- ^ Associated Press Newswires. "Onyx Pharmaceuticals licenses potential cancer autoimmune drugs for $25 million upfront." 7 January 2009.
- ^ http://www.onyx-pharm.com/wt/page/pr_1231274458
- ^ http://clinicaltrials.gov/ct2/results?term=SB1518
- ^ Pfizer's Development Pipeline. Last updated 31 March 2009 and accessed here: http://media.pfizer.com/files/research/pipeline/2009_0331/pipeline_2009_0331.pdf
External links[edit]